EUCTR2016-000171-24-SK进行中（未招募）1 期
Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.
árodný onkologický ústav0 个研究点目标入组 43 人开始时间: 2016年4月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1)Signed written informed consent
- •2)Men aged 18 years or older
- •3)ECOG performance status: 0-1,
- •4)Histologically confirmed extracranial primary germ cell cancer, seminoma, or nonseminoma
- •5)Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin) on sequential measurement or biopsy-proven unresectable germ cell cancer
- •6)Refractory GCTs e.g. patients relapsing after high-dose chemotherapy or for patients non fit enough for high-dose chemotherapy
- •7)Primary mediastinal GCTs in first relapse
- •8)Patient’s disease must not be amenable to cure with either surgery or chemotherapy in the opinion of investigator,
- •9)Measurable disease radiologically
- •10)Adequate hematologic function defined by ANC > 1500/mm3, platelet count > 100 000/mm3 and hemoglobin level > 9g/dl.
- •11)Adequate liver function defined by a total bilirubin level < 1.5 ULN, and ALT, AST < 3 ULN or < 5 in case of liver metastases. For subjects with Gilbert's syndrome bilirubin > 1.5 × ULN is allowed if no symptoms of compromised liver function are present
- •12)Adequate renal function: measured or calculated (by Cockcroft formula) creatinine clearance > 50 ml/min. Cockcroft formula: CLcr = [(140-age) x weight(Kg)]/[72 x creatinine (mg/dl)]
- •13)At least 4 weeks must have elapsed since the last radiotherapy and/or chemotherapy before study entry,
- •14)At least 4 weeks must have elapsed since the last major surgery
- •15)Complete recovery from prior surgery, and/or reduction of all adverse events from previous systemic therapy or radiotherapy to grade 1,
- •16)Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 43
排除标准
- •1)Patients who do not fit inclusion criteria
- •2)Other prior malignancy except successfully treated nonmelanoma skin cancer
- •3)Prior PARP1 inhibitor
- •4)Other concurrent approved or investigational anticancer treatment, including surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or immunotherapy
- •5)Female patients
- •6)Patients infected by the Human Immunodeficiency Virus (HIV)
- •7)Patients with other severe acute or chronic medical condition, or laboratory abnormality that would impair, in the judgment of investigator, excess risk associated with study treatment, or which, in judgment of the investigator, would make the patient inappropriate for entry into this study
- •8)Inability of oral intake, or drug absorbtion (e.g. malabsorption syndrome)
- •9)Hypersensitivity to any compound of the drug
- •10)Sexually active men not using highly effective birth control if their partners are women of child-bearing potential
- •11)Patients with history of or current CNS metastasis
- •12)Patients with history of seizures
研究者
相似试验
招募中
2 期
A Phase II study of Gemcitabine, Cisplatin and Bevacizumab for the patients with first recurrent and refractory ovarian clear cell carcinomaJPRN-UMIN000051087Kansai Clinical Oncology Group(KCOG)28
招募中
2 期
Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphomarelapsed or refractory non-Hodgkin's lymphomaJPRN-UMIN000015998Gifu University Hospital20
尚未招募
不适用
Phase I study of gemcitabine and carboplatin plus sorafenib in patients with advanced solid tumorsadvanced solid tumors10027655CancerNL-OMON31053Antoni van Leeuwenhoek Ziekenhuis28
进行中（未招募）
2 期
GHG-GCDrelapsed or refractory non-Hodgkin's lymphomaJPRN-jRCT1041230085Tsurumi Hisashi20
招募中
2 期
Biliary tract cancer cross-over studybiliary tract cancerJPRN-jRCT1041230014Yamashita Tatsuya50